Currently, immune checkpoint inhibitor (ICI) therapy targeting anti-PD-1 or its ligand anti-PD-L1 is a key step in combination regimens aimed at improving the prognosis of HCC patients (59). The gene discussed is CD274; the disease is hepatocellular carcinoma.